IP Library › Granted Patent US 7,803,571
Granted Patent B2
US 7,803,571 · App. 10/918,015 · Granted Sep 28, 2010

Method for identifying IRS inhibitors or agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,803,571
App. No.
10/918,015
Granted
Sep 28, 2010
Kind
B2
Abstract

The present invention relates to a method for the identification of an IRS protein kinase inhibitor, comprising the steps of a) bringing into contact PKC-ζ with at least one IRS peptide comprising at least one PKC-ζ-Ser-phosphorylation site in the presence of at least one possible inhibitor, and b) measuring the phosphorylation of the PKC-ζ-Ser-phosphorylation site.

Claims (8)

1. A method for identifying an IRS protein kinase inhibitor, the method comprising the steps of

a) contacting, in the presence of at least one possible inhibitor, PKC-ζ with at least one IRS peptide comprising amino acid sequence of SEQ ID NO:17 comprising at least one PKC-ζ-Ser-phosphorylation site, and

b) measuring the phosphorylation of a PKC-ζ-Ser-phosphorylation site at a residue selected from the group consisting of residues 498, 570, and 612, wherein phosphorylation at one or more of residues 498, 570 or 612 inhibits insulin-stimulated tyrosine phosphorylation of the IRS peptide or inhibits interaction of p85α regulatory subunit of phosphatidylinositol 3-kinase with the IRS peptide.

2. The method of claim 1 , wherein a reduced phosphorylation of the PKC-ζ-Ser-phosphorylation site compared to the phosphorylation in the absence of the at least one possible inhibitor is indicative for the inhibitory properties of the possible inhibitor.

3. The method of claim 1 , wherein the PKC-ζ is of mammalian origin.

4. The method of claim 3 , wherein the PKC-ζ is of human or rodent origin.

5. The method of claim 4 , wherein the PKC-ζ is of rat origin.

6. The method of claim 1 , wherein the possible inhibitor is selected from the group consisting of antibodies, binding peptides, and low molecular weight compounds.